A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan

Miwa Haranaka,Joon Young Song,Kuo-Chin Huang,Richard de Solom,Masako Yamaji, Kathleen McElwee, Mary Kline,Masakazu Aizawa,Yahong Peng, Ingrid Scully,Osamu Kogawara,William C. Gruber,Daniel A. Scott,Wendy Watson

Vaccine（2024）

引用 0|浏览3

暂无评分

摘要

•PCV20 elicits robust immune responses in East Asian participants ≥ 60 years old.•PCV20 had a similar safety and tolerability profile to that of PCV13.•These data extend the results of key PCV20 phase 3 trials to East Asian populations.

查看译文

关键词

Asian,20-valent pneumococcal conjugate vaccine,Streptococcus pneumoniae,Immunogenicity,Safety,Clinical study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan

A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan